124 related articles for article (PubMed ID: 20076850)
1. Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Olsson SB; Rasmussen LH; Tveit A; Jensen E; Wessman P; Panfilov S; Wåhlander K
Thromb Haemost; 2010 Mar; 103(3):604-12. PubMed ID: 20076850
[TBL] [Abstract][Full Text] [Related]
2. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy.
Lip GY; Rasmussen LH; Olsson SB; Zetterstrand S; Stahre C; Bylock A; Aunes-Jansson M; Eriksson U; Wåhlander K;
Thromb Res; 2011 Feb; 127(2):91-9. PubMed ID: 21172721
[TBL] [Abstract][Full Text] [Related]
3. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
Halperin JL
J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
[TBL] [Abstract][Full Text] [Related]
4. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.
Lip GY; Rasmussen LH; Olsson SB; Jensen EC; Persson AL; Eriksson U; Wåhlander KF;
Eur Heart J; 2009 Dec; 30(23):2897-907. PubMed ID: 19690349
[TBL] [Abstract][Full Text] [Related]
5. Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects.
Johansson S; Cullberg M; Eriksson UG; Elg M; Dunér K; Jensen E; Wollbratt M; Wåhlander K
Int J Clin Pharmacol Ther; 2011 Apr; 49(4):258-67. PubMed ID: 21429440
[TBL] [Abstract][Full Text] [Related]
6. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
Diener HC;
Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
[TBL] [Abstract][Full Text] [Related]
7. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
[TBL] [Abstract][Full Text] [Related]
8. Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.
Lip GY; Rasmussen LH; Olsson SB; Jensen E; Hamrén B; Eriksson UG; Wåhlander K
Br J Clin Pharmacol; 2015 Dec; 80(6):1362-73. PubMed ID: 26174611
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
ROCKET AF Study Investigators
Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
[TBL] [Abstract][Full Text] [Related]
10. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
Halperin JL;
Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
[TBL] [Abstract][Full Text] [Related]
11. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
Fox KA; Piccini JP; Wojdyla D; Becker RC; Halperin JL; Nessel CC; Paolini JF; Hankey GJ; Mahaffey KW; Patel MR; Singer DE; Califf RM
Eur Heart J; 2011 Oct; 32(19):2387-94. PubMed ID: 21873708
[TBL] [Abstract][Full Text] [Related]
12. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
Albers GW;
Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
[TBL] [Abstract][Full Text] [Related]
13. Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists.
Wolzt M; Eriksson UG; Gouya G; Leuchten N; Kapiotis S; Elg M; Schützer KM; Zetterstrand S; Holmberg M; Wåhlander K
Thromb Res; 2012 Apr; 129(4):e83-91. PubMed ID: 21925716
[TBL] [Abstract][Full Text] [Related]
14. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials.
Ford GA; Choy AM; Deedwania P; Karalis DG; Lindholm CJ; Pluta W; Frison L; Olsson SB;
Stroke; 2007 Nov; 38(11):2965-71. PubMed ID: 17885258
[TBL] [Abstract][Full Text] [Related]
15. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Selçuk H; Selçuk MT; Maden O
Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
[TBL] [Abstract][Full Text] [Related]
16. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
[TBL] [Abstract][Full Text] [Related]
17. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
Salazar CA; del Aguila D; Cordova EG
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD009893. PubMed ID: 24677203
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Pehrsson S; Johansson K; Kjaer M; Elg M
Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
[TBL] [Abstract][Full Text] [Related]
19. Ximelagatran in prevention of cardiovascular events.
Molckovsky D; Boucher M
Issues Emerg Health Technol; 2004 Nov; (62):1-4. PubMed ID: 15565751
[TBL] [Abstract][Full Text] [Related]
20. Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose--a meta-analysis.
Perret-Guillaume C; Wahl DG
Thromb Haemost; 2004 Feb; 91(2):394-402. PubMed ID: 14961170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
